Skip to main content

Table 1 Second-line drug susceptibility results for patient 1 and 2

From: Extensively drug resistant tuberculosis in Mali: a case report

  Sample collection date MTBDRplus
rpoB
MTBDRplus
katG
MTBDRplus
inhA
MTBDRsld
gyrA
MTBDRsld
rrs
MTBDRsld
eis
Patient 1 May 2016 MUT1
(D516V)
MUT1
(S315T)
MUT3B
(T8A)
MUT3C
(D94G)
MUT1
(A1401G)
WT
Patient 2 May 2016 MUT1
(D516V)
WT MUT3B
(T8A)
MUT3C
(D94G)
MUT1
(A1401G)
WT
Patient 3 Feb 2017 MUT1
(D516V)
MUT1
(S315T)
MUT3B
(T8A)
MUT3C
MUT3B
(D94G)
MUT1
(A1401G)
WT
  1. “Point mutations in: the rpoB gene confer resistance to rifampicin; katG gene and in the inhA gene promoter confer resistance to isoniazid; gyrA and gyrB confer resistance to fluoroquinolones; and rrs confers resistance to kanamycin” WT = wild type (no resistance). MUT = mutation in position 1, position 3B, or position 3C of the gene, with specific mutation indicated